"The Self in Regenerys Self® isn't a brand suffix. It's the entire point."
Regenerys Self® is the injectable application of Tissue & Cell Technologies' Adiposet® platform — a cryopreservation technology validated at 85–95% post-thaw cell viability, built over a decade of clinical practice in reconstructive surgery.
Regenerys Self® is the injectable commercial application of a cryopreservation platform that Tissue & Cell Technologies has developed and validated over more than a decade of clinical practice in autologous fat banking for reconstructive surgery.
The Adiposet® platform was originally built for breast reconstruction banking — storing autologous fat at its biological best for post-oncological reconstruction. The clinical standard developed for reconstruction is what now underpins every Regenerys Self® treatment.
Future innovations in processing, targeted delivery, and expanded therapeutic applications are already in development — reaching beyond cosmetics into true regeneration. What we bank today, tomorrow's medicine will only make more powerful. More information on the full T&CT platform at tissueandcell.tech ↗
Tissue & Cell Technologies (T&CT Ltd) is a Cambridge-based medtech company — HTA Licensed, MHRA Regulated, GMP compliant — built on over a decade of clinical work in autologous fat banking for reconstructive surgery.
T&CT's US patient samples are processed and stored at our Dallas, Texas GMP facility. UK, European, and Middle Eastern patients' sample are processed and stored at our Sheffield GMP facility. Both operate under continuous quality monitoring and regular regulatory inspection.
Clinical partnerships span NHS teaching hospitals and internationally recognised academic medical centres
Full information on T&CT's wider platform — including fat banking for reconstruction, stem cell services, and the scientific advisory board — is at tissueandcell.tech ↗
Find an approved clinic, explore the safety framework, or contact Tissue & Cell Technologies directly.